News | May 05, 2023
India is emerging as a favourable destination to conduct clinical trials: PwC-USAIC Report
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Subscribe To Our Newsletter & Stay Updated
